MCID: STM006
MIFTS: 50

Stomach Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Stomach Disease

MalaCards integrated aliases for Stomach Disease:

Name: Stomach Disease 12 15 17
Stomach Diseases 44 72
Gastropathy 12 55
Stomach Disorders 43
Stomach Disorder 12
Gastric Disorder 55
Gastric Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:76
MeSH 44 D013272
NCIt 50 C26886
SNOMED-CT 68 29384001
UMLS 72 C0038354

Summaries for Stomach Disease

MedlinePlus : 43 Your stomach is an organ between your esophagus and small intestine. It is where digestion of protein begins. The stomach has three tasks. It stores swallowed food. It mixes the food with stomach acids. Then it sends the mixture on to the small intestine. Most people have a problem with their stomach at one time or another. Indigestion and heartburn are common problems. You can relieve some stomach problems with over-the-counter medicines and lifestyle changes, such as avoiding fatty foods or eating more slowly. Other problems like peptic ulcers or GERD require medical attention. You should see a doctor if you have any of the following: Blood when you have a bowel movement Severe abdominal pain Heartburn not relieved by antacids Unintended weight loss Ongoing vomiting or diarrhea NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Stomach Disease, also known as stomach diseases, is related to functional gastric disease and gastritis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Stomach Disease is PTGS2 (Prostaglandin-Endoperoxide Synthase 2), and among its related pathways/superpathways are WNT Signaling and Cell cycle Cell cycle (generic schema). The drugs Propofol and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include kidney, small intestine and testes, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Disease Ontology : 12 A gastrointestinal system disease that is located in the stomach.

Wikipedia : 75 Stomach diseases include gastritis, gastroparesis, diarrhea, Crohn's disease and various... more...

Related Diseases for Stomach Disease

Diseases related to Stomach Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 functional gastric disease 34.5 HRH2 GHRL ATP4A ATP12A
2 gastritis 33.0 S100A8 PTGS2 HRH2 GHRL GAST
3 active peptic ulcer disease 31.5 PTGS2 PTGS1 HRH2 ATP4A ATP12A
4 lymphoma, mucosa-associated lymphoid type 31.2 S100A8 ATP4A ATP12A
5 microinvasive gastric cancer 31.2 CDH1 ATP4A ATP12A
6 gastric ulcer 31.1 PTGS2 PTGS1 MMP7 HRH2 GAST
7 duodenal ulcer 31.0 S100A8 HRH2 GAST
8 atrophic gastritis 31.0 S100A8 GHRL GAST
9 peptic ulcer disease 31.0 S100A8 PTGS2 HRH2 GHRL GAST ATP4A
10 granulomatous gastritis 31.0 GAST ATP4A ATP12A
11 familial adenomatous polyposis 30.8 PTGS2 PTGS1 CDH1
12 gastroesophageal reflux 30.8 PTGS2 PTGS1 HRH2 GHRL GAST
13 gastric antral vascular ectasia 30.7 ATP4A ATP12A
14 duodenitis 30.7 GAST ATP4A ATP12A
15 dyspepsia 30.7 PTGS2 PTGS1 HRH2 GHRL
16 bile reflux 30.6 PTGS2 ATP4A ATP12A
17 peptic esophagitis 30.6 HRH2 ATP4A ATP12A
18 esophageal cancer 30.6 TIMP1 PTGS2 MMP7 ERBB2 CDH1
19 hernia, hiatus 30.6 ATP4A ATP12A
20 gastrointestinal system disease 30.5 S100A8 PTGS2 GHRL GAST ERBB2 CDH1
21 gastric cancer 30.4 S100A8 PTGS2 MMP7 GKN2 GAST ERBB2
22 gastric adenocarcinoma 30.4 S100A8 PTGS2 GAST ERBB2 CDH1
23 large intestine cancer 30.2 TIMP1 PTGS2 MMP7 GAST ERBB2 CDH1
24 peptic ulcer perforation 30.2 S100A8 PTGS2 HRH2 GAST ATP4A ATP12A
25 non-hypoproteinemic hypertrophic gastropathy 12.4
26 gastritis, familial giant hypertrophic 11.8
27 fungal esophagitis 10.9 ATP4A ATP12A
28 gastroduodenal crohn's disease 10.9 ATP4A ATP12A
29 diclofenac allergy 10.9 ATP4A ATP12A
30 neonatal candidiasis 10.9 ATP4A ATP12A
31 squamous papillomatosis 10.9 ATP4A ATP12A
32 photoallergic dermatitis 10.9 PTGS2 ATP4A ATP12A
33 aspiration pneumonitis 10.9 HRH2 ATP4A ATP12A
34 aspirin resistance 10.9 PTGS2 PTGS1
35 toxic megacolon 10.9 ATP4A ATP12A
36 breast cystic hypersecretory carcinoma 10.9 ERBB2 CDH1
37 mid-dermal elastolysis 10.9 TIMP1 MMP7
38 laryngitis 10.9 HRH2 ATP4A ATP12A
39 chronic laryngitis 10.9 HRH2 ATP4A ATP12A
40 pancreatic steatorrhea 10.9 GHRL ATP4A ATP12A
41 pylorospasm 10.9 GHRL GAST
42 oral submucous fibrosis 10.9 TIMP1 PTGS2 CDH1
43 gastrointestinal neuroendocrine benign tumor 10.9 GAST ATP4A ATP12A
44 gastric neuroendocrine neoplasm 10.9 GAST ATP4A ATP12A
45 laryngeal disease 10.8 CDH1 ATP4A ATP12A
46 acute laryngitis 10.8 ATP4A ATP12A
47 esophageal candidiasis 10.8 ATP4A ATP12A
48 ductal carcinoma in situ 10.8 PTGS2 ERBB2 CDH1
49 blind loop syndrome 10.8 HRH2 GHRL ATP4A ATP12A
50 esophagus adenocarcinoma 10.8 PTGS2 ERBB2 ATP4A ATP12A

Graphical network of the top 20 diseases related to Stomach Disease:



Diseases related to Stomach Disease

Symptoms & Phenotypes for Stomach Disease

UMLS symptoms related to Stomach Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, signs and symptoms, digestive, dyspepsia, heartburn, gastrointestinal gas, stomach ache

MGI Mouse Phenotypes related to Stomach Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 ATP12A ATP4A CDH1 ERBB2 GAST GHRL
2 homeostasis/metabolism MP:0005376 9.97 ATP12A ATP4A CDH1 ERBB2 GAST GHRL
3 endocrine/exocrine gland MP:0005379 9.96 ATP4A CDH1 ERBB2 GAST GHRL GKN2
4 immune system MP:0005387 9.65 ATP4A CDH1 GAST GKN2 HDC MMP7
5 neoplasm MP:0002006 9.28 ATP4A CDH1 ERBB2 GAST GKN2 MMP7

Drugs & Therapeutics for Stomach Disease

Drugs for Stomach Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Propranolol Approved, Investigational Phase 4 525-66-6 4946
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Metronidazole Approved Phase 4 443-48-1 4173
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
16
Pantoprazole Approved Phase 4 102625-70-7 4679
17
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
18
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
19 Rebamipide Investigational Phase 4 90098-04-7
20 Anti-Anxiety Agents Phase 4
21 GABA Agents Phase 4
22 Hypnotics and Sedatives Phase 4
23 Adjuvants, Anesthesia Phase 4
24 GABA Modulators Phase 4
25 Anesthetics Phase 4
26 Anesthetics, General Phase 4
27 Anesthetics, Intravenous Phase 4
28 Adrenergic Agonists Phase 4
29 Hemostatics Phase 4
30 Sympathomimetics Phase 4
31 Adrenergic beta-Agonists Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Epinephryl borate Phase 4
34 Mydriatics Phase 4
35 Anti-Asthmatic Agents Phase 4
36 Vasoconstrictor Agents Phase 4
37 Bronchodilator Agents Phase 4
38 Antirheumatic Agents Phase 4
39 Dermatologic Agents Phase 4
40 Antihypertensive Agents Phase 4
41 Hormones Phase 4
42 Adrenergic alpha-Antagonists Phase 4
43 Adrenergic beta-Antagonists Phase 4
44 Adrenergic alpha-1 Receptor Antagonists Phase 4
45 Adrenergic Antagonists Phase 4
46 Adrenergic Agents Phase 4
47 Anti-Arrhythmia Agents Phase 4
48 calcium channel blockers Phase 4
49 Calcium, Dietary Phase 4
50 Immunologic Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
2 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
3 Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy Completed NCT00641004 Phase 4 Rebamipide and Esomeprazole
4 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
5 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
6 Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
7 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
8 Omentopexy With Glubran®2 for Reducing Complications After Laparoscopic Sleeve Gastrectomy: Results of a Prospective Study. Completed NCT03833232 Phase 4
9 Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study Recruiting NCT02476097 Phase 4 Esomeprazole: Nexium® 20mg, Astra Zeneca;Placebo
10 Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial Recruiting NCT03198871 Phase 4 Acetaminophen Injectable Product;Sodium Chloride 0.9%, Intravenous
11 Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced Gastropathy Terminated NCT02788123 Phase 4 bismuth tripotassium dicitrate;pantoprazole
12 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
13 Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs Terminated NCT00443963 Phase 4 Esomeprazole Magnesium
14 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
15 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
16 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
17 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
18 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
19 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study) Completed NCT00745459 Phase 3 NPO-11
20 Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study) Completed NCT00742599 Phase 3 NPO-11;Placebo
21 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial Completed NCT02219529 Phase 3
22 Antidepressant Therapy for Functional Dyspepsia Completed NCT00248651 Phase 2, Phase 3 Amitriptyline;Escitalopram;Placebo
23 A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
24 Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy: Single Center, Prospective, Double Blinded, Randomized Controlled Trial Completed NCT03342118 Phase 3 Phloroglucin(Flospan®);Normal saline
25 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
26 Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial Unknown status NCT02846155 Phase 2 simethicone;simethicone combined with pronase
27 A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments Completed NCT01576380 Phase 2 TKI258
28 A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection Recruiting NCT03238612 Phase 2 FFA, clarithromycin, oseltamivir;Oseltamivir alone
29 Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial. Recruiting NCT03549494 Phase 2
30 Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Recruiting NCT03064490 Phase 2 Pembrolizumab
31 the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function Not yet recruiting NCT03910647 Phase 2 pantoprazole
32 Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test Not yet recruiting NCT04022837 Phase 2 Pantoprazole 40mg
33 Functional Consequences and Therapeutic Intervention in Hampered Production of Cysteine, Glutathione and Taurine in Classical Homocystinuria Not yet recruiting NCT04015557 Phase 1, Phase 2 Acetaminophen;N-acetylcysteine
34 Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy Terminated NCT00142974 Phase 2 Tegaserod
35 A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas Terminated NCT03122548 Phase 2
36 A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression Completed NCT00744419 Phase 1 pantoprazole
37 A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression Recruiting NCT03255070 Phase 1 ARX788
38 CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging Unknown status NCT03092414
39 Gastric Emptying: in Vivo Studies in Healthy Volunteers (Using Scrambled Egg and Porridge) to Determine Reliable Normal Ranges Unknown status NCT02994472
40 Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding Unknown status NCT03212872
41 An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders Unknown status NCT00777439 Domperidone
42 Comparison of Effectiveness of "Sekanjabin e Safarjali" (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction Unknown status NCT02179775 propranolol;Quince's oxymel;placebo
43 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing: a Population-based Randomized Study Unknown status NCT01741363
44 Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses Completed NCT02105506 Tachosil patch
45 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859
46 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study. Completed NCT01477320 Pantoprazole 40 mg IV daily and tube feed.
47 A Pilot Study to Investigate Whether Intragastric Pressure During Food Intake Can be Measured Using an Intragastric Bag in Healthy Volunteers Completed NCT03500887
48 Risk Factors for Gastric Disease in Pediatric H. Pylori Completed NCT00212225
49 Feasibility and Performances of Spleen Stiffness Measurement as Surrogate Marker for Oesophageal Varices in Cirrhotic Patients. Completed NCT02180113
50 Non-invasive Methods to Predict Portal Hypertensive Gastropathy in Patients With Cirrhosis Completed NCT03513900

Search NIH Clinical Center for Stomach Disease

Cochrane evidence based reviews: stomach diseases

Genetic Tests for Stomach Disease

Anatomical Context for Stomach Disease

MalaCards organs/tissues related to Stomach Disease:

41
Kidney, Small Intestine, Testes, Liver, Bone, Spleen, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Stomach Disease:

19
Stomach

Publications for Stomach Disease

Articles related to Stomach Disease:

(show top 50) (show all 430)
# Title Authors PMID Year
1
Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities. 17
31185961 2019
2
The usefulness of inflammatory biomarkers in diagnosing child and adolescent's gastritis: STROBE compliant article. 17
31261556 2019
3
Endoscopic submucosal dissection in a patient with idiopathic mesenteric phlebosclerosis. 17
31314205 2019
4
[Stomach disease and ghrelin]. 9 38
15506414 2004
5
Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. 38
31368293 2019
6
History of gastroesophageal reflux disease in patients with suspected coronary artery disease. 38
30993440 2019
7
Evaluation of hepatotoxicity potential of a potent traditional Tibetan medicine Zuotai. 38
30580024 2019
8
[Risk factors of oral Helicobacter pylori infection among children in two kindergartens in Suzhou and the effects of oral cleaning on reducing oral Helicobacter pylori infection]. 38
30854823 2019
9
Investigation on correlations of serum IL-26 with diagnosis and staging of gastric cancer. 38
30941972 2019
10
[Effect of modified Zhengqi Powder in treating chronic gastritis and on patients' life quality and inflammatory factors]. 38
30868830 2019
11
N-Alkylamides from Piper longum L. and their stimulative effects on the melanin content and tyrosinase activity in B16 melanoma cells. 38
30623685 2019
12
A Clinical Trial on Oral H. pylori Infection of Preschool Children. 38
30610045 2018
13
[Analysis on medication regularity and action mechanism of Tibetan medicine in treatment of spleen and stomach diseases based on data mining and integrated pharmacology]. 38
30200743 2018
14
Pistacia atlantica Desf. A review of its traditional uses, phytochemicals and pharmacology. 38
30364651 2018
15
Effect of Pistacia atlantica kurdica gum on diabetic gastroparesis symptoms: a randomized, triple-blind placebo-controlled clinical trial. 38
30128090 2018
16
Calycophyllum spruceanum BENTH ameliorates acute inflammation in mice. 38
29567276 2018
17
[Research progress of Tibetan medicine "Zha-xun"]. 38
29751700 2018
18
Levels of malondialdehyde in the gastric juice: Its association with Helicobacter pylori infection and stomach diseases. 38
29315971 2018
19
Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials. 38
29491257 2018
20
In situ quantification and evaluation of ClO-/H2S homeostasis in inflammatory gastric tissue by applying a rationally designed dual-response fluorescence probe featuring a novel H+-activated mechanism. 38
28394381 2017
21
Application of Micellar Extraction for Isolation of Famotidine from Aqueous Samples Prior to its Chromatographic Determination. 38
29200812 2017
22
[Expressions of MMP-7 and TIMP-1 in Chronic Stomach Disease Patients with Different Syndromes of Chinese Medicine]. 38
30695426 2017
23
Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of Helicobacter pylori Infection in Healthy Individuals. 38
27865295 2016
24
Image enhancement based on in vivo hyperspectral gastroscopic images: a case study. 38
27206742 2016
25
Trichloromethane fraction of Incarvillea compacta induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells. 38
27595569 2016
26
Ethnobotany, chemical constituents and biological activities of the flowers of Hydnora abyssinica A.Br. (Hydnoraceae). 38
27209704 2016
27
Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. 38
26709179 2016
28
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. 38
25986943 2016
29
Effect of propolis in gastric disorders: inhibition studies on the growth of Helicobacter pylori and production of its urease. 38
27233102 2016
30
[Midnight-noon ebb-flow acupuncture at stomach meridian of foot-yangming: a fMRI study]. 38
26964172 2015
31
Alterations in Th17 and the Respective Cytokine Levels in Helicobacter pylori-Induced Stomach Diseases. 38
25908492 2015
32
Prevalence of Chronic Disabling Noncancer Pain and Associated Demographic and Medical Variables: A Cross-Sectional Survey in the General German Population. 38
25411861 2015
33
Detection of oral Helicobacter Pylori infection using saliva test cassette. 38
26649012 2015
34
Generation of stomach tissue from mouse embryonic stem cells. 38
26192439 2015
35
The incidence of acute gastrointestinal illness in Sweden. 38
25969165 2015
36
PERIODONTAL POCKETS AS A RESERVOIR OF HELICOBACTER PYLORI CAUSING RELAPSE OF GASTRIC ULCER: A REVIEW OF THE LITERATURE. 38
26511191 2015
37
The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases? 38
26137299 2015
38
Evaluation of bile reflux in HIDA images based on fluid mechanics. 38
25754361 2015
39
Evaluation of the medicinal properties of Cyrtocarpa procera Kunth fruit extracts. 38
25887560 2015
40
Antimicrobial activity, toxicity and selectivity index of two biflavonoids and a flavone isolated from Podocarpus henkelii (Podocarpaceae) leaves. 38
25293523 2014
41
Effects of Thymus hirtus sp. algeriensis Boiss. et Reut. (Lamiaceae) essential oil on healing gastric ulcers according to sex. 38
25159191 2014
42
Microbiota in the stomach: new insights. 38
24245792 2014
43
[Effect of different acupoint prescriptions on prevention and treatment of stress gastric ulcer]. 38
24796050 2014
44
Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer. 38
24895832 2014
45
Pathway of programmed cell death and oxidative stress induced by β-hydroxybutyrate in dairy cow abomasum smooth muscle cells and in mouse gastric smooth muscle. 38
24801711 2014
46
Drinking severity and its association with nutrition risk among African American women. 38
24853360 2014
47
Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients. 38
23801858 2013
48
[Detection of the markers of herpesvirus infections in stomach diseases of inhabitants of the Republic of Mordovia]. 38
24006634 2013
49
[Comparative morphology of the gastric mucosa in asthmatic patients using inhaled glucocorticosteroid therapy]. 38
24006758 2013
50
[The prevalence of epidemic diseases in Inner Mongolia region and the social vicissitude of Mongolian ethnic group]. 38
24135476 2013

Variations for Stomach Disease

Expression for Stomach Disease

Search GEO for disease gene expression data for Stomach Disease.

Pathways for Stomach Disease

GO Terms for Stomach Disease

Cellular components related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TIMP1 SERPINA3 S100A8 MMP7 MIR338 GKN2
2 secretory granule lumen GO:0034774 9.13 SERPINA3 S100A8 GHRL

Biological processes related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 wound healing GO:0042060 9.5 TIMP1 S100A8 ERBB2
2 cellular sodium ion homeostasis GO:0006883 9.43 ATP4A ATP12A
3 response to organic substance GO:0010033 9.43 TIMP1 PTGS2 CDH1
4 prostaglandin biosynthetic process GO:0001516 9.4 PTGS2 PTGS1
5 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.37 ATP4A ATP12A
6 sodium ion export across plasma membrane GO:0036376 9.16 ATP4A ATP12A
7 cellular potassium ion homeostasis GO:0030007 8.96 ATP4A ATP12A
8 cyclooxygenase pathway GO:0019371 8.62 PTGS2 PTGS1

Molecular functions related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP4A ATP12A
2 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1

Sources for Stomach Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....